Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and ...more

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio® has also organized over 30 conferences focused on investment and partnering, including the highly successful ChinaBio® Partnering Forum which draws over 850 attendees from around the world to China each spring. Greg is also co-founder of two angel investment groups that have funded over 45 biotechnology and medical device companies in the U.S. and China, and Executive Editor of ChinaBio® Today, the most widely read source for China life science news. Greg lives and works in Shanghai but visits San Diego several times a year to enjoy the blue skies and sandy beaches. - See more here. China has become the #2 pharmaceutical market years ahead of projections and continues to be the fastest growing market in the world. The China government is investing over $80 billion dollars a year into life science and healthcare development through over 160 government funding programs. VC investment, M&A transactions and cross-border partnering deals all set new records in China in 2014, contributing over $20B in value to the industry. ChinaBio® Today focuses exclusively on the rapidly evolving life science industry in China, including biotech, pharma, medical device, diagnostics, services and tools. From our offices in Shanghai and San Diego, our industry analysts provide daily news, commentary and analysis on public and private China life science companies, as well as events and global issues affecting the China market.less